Unveiling of abstracts for December’s haematology meeting sent Crispr up and Allogene down, but the biggest beneficiary was private.
Sobi picking up rights to Apellis’s complement factor C3 inhibitor adds to earlier deals focused on C5, D and anti-FcRn antibodies.
Important clinical data are expected in the fourth quarter from biotech companies including Madrigal, Arena, Rhythm and Forma.
Could Pfizer/Sangamo’s project be facing the same durability issues as Biomarin’s Roctavian?
Cardiac safety threatens to derail the company’s new anaemia pill, but should rival Fibrogen be celebrating?